JOP20230128A1 - مركبات صيدلانية - Google Patents
مركبات صيدلانيةInfo
- Publication number
- JOP20230128A1 JOP20230128A1 JOJO/P/2023/0128A JOP20230128A JOP20230128A1 JO P20230128 A1 JOP20230128 A1 JO P20230128A1 JO P20230128 A JOP20230128 A JO P20230128A JO P20230128 A1 JOP20230128 A1 JO P20230128A1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- pharmaceutical compounds
- presented
- muscarinic
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2020191.9A GB202020191D0 (en) | 2020-12-18 | 2020-12-18 | Pharmaceutical compounds |
| PCT/GB2021/053372 WO2022129951A1 (en) | 2020-12-18 | 2021-12-20 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20230128A1 true JOP20230128A1 (ar) | 2023-06-06 |
Family
ID=74221349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2023/0128A JOP20230128A1 (ar) | 2020-12-18 | 2023-06-06 | مركبات صيدلانية |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11999745B2 (enExample) |
| EP (1) | EP4263536A1 (enExample) |
| JP (1) | JP7730369B2 (enExample) |
| KR (1) | KR20230121830A (enExample) |
| CN (1) | CN116848109B (enExample) |
| AU (1) | AU2021404194A1 (enExample) |
| CA (1) | CA3202054A1 (enExample) |
| CL (1) | CL2023001755A1 (enExample) |
| CO (1) | CO2023007838A2 (enExample) |
| CR (1) | CR20230256A (enExample) |
| DO (1) | DOP2023000125A (enExample) |
| EC (1) | ECSP23044370A (enExample) |
| GB (1) | GB202020191D0 (enExample) |
| IL (1) | IL303484A (enExample) |
| JO (1) | JOP20230128A1 (enExample) |
| MX (1) | MX2023007140A (enExample) |
| PE (1) | PE20240646A1 (enExample) |
| WO (1) | WO2022129951A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2780015B1 (en) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369184A (en) | 1980-01-24 | 1983-01-18 | Janssen Pharmaceutica N.V. | 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives |
| JPS56110674A (en) | 1980-01-24 | 1981-09-01 | Janssen Pharmaceutica Nv | Novel 11*cyclohexyl**44aryll44piperidine carboxylic acid derivative |
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| GB9300194D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
| US5446051A (en) | 1994-05-31 | 1995-08-29 | Eli Lilly And Company | Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists |
| JP2002515008A (ja) | 1994-10-27 | 2002-05-21 | メルク エンド カンパニー インコーポレーテッド | ムスカリン・アンタゴニスト |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| WO1997016187A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine antagonists |
| US5854245A (en) | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| DE69734774D1 (de) | 1996-08-26 | 2006-01-05 | Pfizer | Spirocyclische dopaminrezeptor-subtyp-liganden |
| JP2002505684A (ja) | 1997-06-18 | 2002-02-19 | メルク エンド カンパニー インコーポレーテッド | α１ａアドレナリン受容体拮抗薬 |
| GB9715892D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
| WO1999032486A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| WO1999032479A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists |
| AU2307999A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| WO1999032489A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| CZ286152B6 (cs) | 1998-03-13 | 2000-01-12 | Miroslav Ing. Csc. Vlček | Transparentní a semitransparentní difrakční prvky |
| KR100439357B1 (ko) | 1999-05-04 | 2004-07-07 | 쉐링 코포레이션 | Ｃｃｒ５ 길항제로서 유용한 피페리딘 유도체 |
| US6387930B1 (en) | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| BR0010593A (pt) | 1999-05-04 | 2002-02-13 | Schering Corp | Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| ES2199856T3 (es) | 1999-09-13 | 2004-03-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Nuevos compuestos heterociclicos, utiles como inhibidores reversibles de cisteina proteasas. |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| US6699880B1 (en) | 1999-10-13 | 2004-03-02 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
| US7163938B2 (en) | 2000-11-28 | 2007-01-16 | Eli Lilly And Company | Substituted carboxamides |
| JPWO2002085890A1 (ja) | 2001-04-20 | 2004-08-12 | 萬有製薬株式会社 | ベンズイミダゾロン誘導体 |
| EP1395257A1 (en) | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| GB0128378D0 (en) | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel Compounds |
| US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| ES2251624T3 (es) | 2001-12-28 | 2006-05-01 | Acadia Pharmaceuticals Inc. | Analogos de la tetrahidroquinolina como los agonistas muscarinicos. |
| US20040171614A1 (en) | 2002-02-06 | 2004-09-02 | Schering-Plough Corporation | Novel gamma secretase inhibitors |
| US7256186B2 (en) | 2002-02-06 | 2007-08-14 | Schering Corporation | Gamma secretase inhibitors |
| PT1489078E (pt) | 2002-03-28 | 2010-02-24 | Mitsubishi Tanabe Pharma Corp | Derivados de benzofurano |
| JPWO2003104230A1 (ja) | 2002-06-07 | 2005-10-06 | 協和醗酵工業株式会社 | 二環性ピリミジン誘導体 |
| HK1079787A1 (zh) | 2002-07-31 | 2006-04-13 | Ranbaxy Laboratories Limited | 用作毒蕈碱受体拮抗剂的3，6-二取代的氮杂双环[3．1．0]己烷衍生物 |
| JP4711391B2 (ja) | 2002-09-30 | 2011-06-29 | ニューロサーチ、アクティーゼルスカブ | 新規１，４−ジアザビシクロアルカン誘導体及びその製造方法 |
| RU2342388C2 (ru) | 2002-11-22 | 2008-12-27 | Джапан Тобакко Инк. | Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием |
| EP1565436B1 (en) | 2002-11-27 | 2012-04-25 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
| WO2004069828A1 (ja) | 2003-02-04 | 2004-08-19 | Mitsubishi Pharma Corporation | ピペリジン化合物およびその医薬用途 |
| MXPA06000441A (es) | 2003-07-17 | 2006-04-05 | Astellas Pharma Inc | Derivado de 2-acilaminotiazole o sal del mismo. |
| JPWO2005037269A1 (ja) | 2003-10-21 | 2006-12-28 | 住友製薬株式会社 | 新規ピペリジン誘導体 |
| CA2554465A1 (en) | 2004-02-05 | 2005-08-25 | Schering Corporation | Piperidine derivatives useful as ccr3 antagonists |
| RU2006132465A (ru) | 2004-02-10 | 2008-03-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Модуляторы хемокинового рецептора ccr5 |
| US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
| JP2008521821A (ja) | 2004-11-29 | 2008-06-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
| JP4774995B2 (ja) | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
| EP1863490A2 (en) | 2005-03-28 | 2007-12-12 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
| EP1900732A4 (en) | 2005-06-24 | 2009-11-18 | Toyama Chemical Co Ltd | NEW NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF |
| AU2006330866A1 (en) | 2005-12-22 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| ES2545907T3 (es) | 2005-12-29 | 2015-09-16 | Abbvie Inc. | Inhibidores de proteína quinasa |
| KR20080098070A (ko) | 2006-02-22 | 2008-11-06 | 버텍스 파마슈티칼스 인코포레이티드 | 무스카린성 수용체의 조절제로서의 스피로 축합된 피페리딘 |
| AU2007221214A1 (en) | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| AU2007284548A1 (en) | 2006-08-15 | 2008-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| US20130012485A1 (en) | 2006-12-22 | 2013-01-10 | Baeschlin Daniel Kaspar | Organic compounds |
| WO2008117229A1 (en) | 2007-03-23 | 2008-10-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| WO2009118370A1 (en) | 2008-03-27 | 2009-10-01 | Janssen Pharmaceutica Nv | Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| MX2011004340A (es) | 2008-10-29 | 2011-05-23 | Gruenenthal Gmbh | Espiroaminas sustituidas. |
| CN102256963B (zh) | 2008-12-19 | 2014-06-11 | 贝林格尔.英格海姆国际有限公司 | 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺 |
| EP2419419B1 (en) | 2009-04-17 | 2014-12-03 | Janssen Pharmaceutica NV | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| WO2011112825A2 (en) | 2010-03-10 | 2011-09-15 | Vanderbilt University | Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same |
| US8822447B2 (en) | 2010-04-22 | 2014-09-02 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
| EP2563127A4 (en) | 2010-04-27 | 2013-11-06 | Merck Sharp & Dohme | PROLYLCARBOXYPEPTIDASE INHIBITORS |
| EP2568812B1 (en) | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| JP2013528180A (ja) | 2010-05-28 | 2013-07-08 | ジーイー・ヘルスケア・リミテッド | 放射性標識化合物及びその製造方法 |
| EP2616074A1 (en) | 2010-09-17 | 2013-07-24 | Array Biopharma, Inc. | Piperidinyl-substituted lactams as gpr119 modulators |
| EP2685828A4 (en) | 2011-03-17 | 2014-08-13 | Merck Sharp & Dohme | SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS |
| JP2013010719A (ja) | 2011-06-30 | 2013-01-17 | Dainippon Sumitomo Pharma Co Ltd | ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途 |
| EP2780015B1 (en) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| CN107098899B (zh) | 2012-09-18 | 2019-09-06 | 赫普泰雅治疗有限公司 | 作为毒蕈碱的m1受体激动剂的二环氮杂化合物 |
| JP6478923B2 (ja) | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート |
| SG11201606269WA (en) | 2014-02-06 | 2016-09-29 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| SG11201706501VA (en) | 2015-02-13 | 2017-09-28 | Suven Life Sciences Ltd | AMIDE COMPOUNDS AS 5-HT<sb>4</sb> RECEPTOR AGONISTS |
| GB201504675D0 (en) | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513740D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US10259787B2 (en) | 2016-10-14 | 2019-04-16 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US10501483B2 (en) | 2017-10-24 | 2019-12-10 | Allergan, Inc. | Enamines and diastereo-selective reduction of enamines |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202103211D0 (en) | 2021-03-08 | 2021-04-21 | Heptares Therapeutics Ltd | Pharmaceutical compounds for use in therapy |
-
2020
- 2020-12-18 GB GBGB2020191.9A patent/GB202020191D0/en not_active Ceased
-
2021
- 2021-12-20 CA CA3202054A patent/CA3202054A1/en active Pending
- 2021-12-20 PE PE2023001903A patent/PE20240646A1/es unknown
- 2021-12-20 MX MX2023007140A patent/MX2023007140A/es unknown
- 2021-12-20 WO PCT/GB2021/053372 patent/WO2022129951A1/en not_active Ceased
- 2021-12-20 AU AU2021404194A patent/AU2021404194A1/en active Pending
- 2021-12-20 CN CN202180093050.7A patent/CN116848109B/zh active Active
- 2021-12-20 JP JP2023536899A patent/JP7730369B2/ja active Active
- 2021-12-20 CR CR20230256A patent/CR20230256A/es unknown
- 2021-12-20 EP EP21836606.0A patent/EP4263536A1/en active Pending
- 2021-12-20 KR KR1020237023911A patent/KR20230121830A/ko active Pending
- 2021-12-20 IL IL303484A patent/IL303484A/en unknown
-
2022
- 2022-07-27 US US17/874,564 patent/US11999745B2/en active Active
-
2023
- 2023-06-06 JO JOJO/P/2023/0128A patent/JOP20230128A1/ar unknown
- 2023-06-15 EC ECSENADI202344370A patent/ECSP23044370A/es unknown
- 2023-06-15 DO DO2023000125A patent/DOP2023000125A/es unknown
- 2023-06-15 CO CONC2023/0007838A patent/CO2023007838A2/es unknown
- 2023-06-15 CL CL2023001755A patent/CL2023001755A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024504252A (ja) | 2024-01-31 |
| AU2021404194A1 (en) | 2023-08-03 |
| AU2021404194A9 (en) | 2024-10-17 |
| PE20240646A1 (es) | 2024-04-04 |
| WO2022129951A1 (en) | 2022-06-23 |
| US11999745B2 (en) | 2024-06-04 |
| JP7730369B2 (ja) | 2025-08-27 |
| MX2023007140A (es) | 2023-08-25 |
| US20220380379A1 (en) | 2022-12-01 |
| IL303484A (en) | 2023-08-01 |
| CL2023001755A1 (es) | 2024-01-05 |
| CR20230256A (es) | 2023-09-29 |
| DOP2023000125A (es) | 2023-08-31 |
| CN116848109B (zh) | 2026-02-10 |
| KR20230121830A (ko) | 2023-08-21 |
| ECSP23044370A (es) | 2023-08-31 |
| EP4263536A1 (en) | 2023-10-25 |
| CA3202054A1 (en) | 2022-06-23 |
| GB202020191D0 (en) | 2021-02-03 |
| CO2023007838A2 (es) | 2023-10-30 |
| CN116848109A (zh) | 2023-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230128A1 (ar) | مركبات صيدلانية | |
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| JOP20230316B1 (ar) | N-(هيدروكسي ألكيل أريل (غير متجانس)) تترا هيدروفيوران كربوكساميدات كمعدلات لقنوات الصوديوم | |
| MX393395B (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo. | |
| EA202191498A1 (ru) | 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение | |
| CO2018002060A2 (es) | Compuestos farmacéuticos | |
| MX2024010092A (es) | Inhibidores del nlrp3 | |
| EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
| MY208400A (en) | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof | |
| EA202192905A1 (ru) | Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли | |
| EA200970065A1 (ru) | Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38 | |
| AR123685A1 (es) | Antagonistas del mrgx2 | |
| MX2025001312A (es) | Formas cristalinas y sales de un agonista del receptor muscarinico | |
| CY1113759T1 (el) | Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2 | |
| EA201891710A1 (ru) | Терапевтические соединения | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| PY2221203A (es) | Derivados de ciclobutilo 1,3-sustituidos y sus usos | |
| CY1112227T1 (el) | Πιπεριδινυλαμινο-πυριδαζινες και η χρηση τους ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2 | |
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
| CL2022002386A1 (es) | Compuestos de amino pirimidina fusionados | |
| SA521421098B1 (ar) | -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| PA8567701A1 (es) | Agonistas del receptor b3-adrenergico |